Association of biomarkers with cardiac events during abiraterone acetate treatment in castration-resistant prostate cancer (CRPC).

e16086 Background: Abiraterone acetate is an effective drug for metastatic CRPC, but serious cardiac adverse events may occur. Objectives: We explored the association between the cardiac biomarkers N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) and Troponin-T (TnT) and cardiac SAEs during abiraterone therapy in patients with CRPC. Methods: Seventeen patients, in a single institution, were treated with abiraterone acetate, 1 g daily, until disease progression. Concomitant treatment with prednisone, then switched to dexametasone plus canrenone, was administered. Blood samples for PSA, NT-proBNP and TnT were obtained at baseline, 1, 3 and 6 months of treatment. Adverse events were evaluated using NCI-CTCAE v 4. Tumor response was assessed by PET-CT and/or contrast enhancement CT scan and PSA. Results: Five patients (29.4%) experienced G3-4 cardiac SAEs after a median of 13 weeks (range 9-32) of treatment. Specifically, pulmonary edema G4, heart failure G3, acute coronary syndrome G3, synus bradycardia ...